Meftal-MR Tablet is a combination medication containing Mefenamic Acid 500 mg and Tizanidine 2 mg, formulated for the management of moderate to severe pain associated with musculoskeletal conditions and spasticity. Mefenamic Acid, a non-steroidal anti-inflammatory drug (NSAID), exerts analgesic, anti-inflammatory, and antipyretic effects by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis involved in pain and inflammation. Tizanidine, a centrally acting alpha-2 adrenergic agonist, provides muscle relaxation by inhibiting motor neurons, effectively reducing muscle spasm and associated discomfort. This synergistic combination offers both pain relief and muscle relaxation, making Meftal-MR suitable for conditions such as back pain, dysmenorrhea, and musculoskeletal spasms. The extended-release formulation ensures sustained therapeutic plasma levels, enhancing patient compliance and symptom control. Meftal-MR should be used under medical supervision, considering contraindications such as hypersensitivity to NSAIDs or tizanidine, hepatic or renal impairment, and concurrent use of interacting medications. Common adverse effects may include dizziness, drowsiness, gastrointestinal disturbances, and dry mouth. Caution is advised when operating machinery or driving. Regular monitoring and adherence to prescribed dosage are essential to minimize risks and optimize therapeutic outcomes.